<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1473">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04412369</url>
  </required_header>
  <id_info>
    <org_study_id>A09565</org_study_id>
    <nct_id>NCT04412369</nct_id>
  </id_info>
  <brief_title>Multi-modality Imaging &amp; Immunophenotyping of COVID-19 Related Myocardial Injury</brief_title>
  <acronym>MIIC-MI</acronym>
  <official_title>Multi-modality Imaging &amp; Immunophenotyping of COVID-19 Related Myocardial Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac Troponin elevation is associated with adverse prognosis in COVID-19. The MIIC-MI&#xD;
      study aims to investigate mechanisms of cardiac injury in COVID-19 using multi-modality&#xD;
      imaging and immunophenotyping to better understand the link with adverse patient outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac Troponin elevation, a marker of acute myocardial injury, has been identified in up to&#xD;
      28% of hospitalized patients with coronavirus disease 2019 (COVID-19) and is associated with&#xD;
      an increased mortality risk. However, the predominant aetiology of myocardial injury relating&#xD;
      to COVID-19 remains unclear. The Troponin leak could either signify direct cardiac&#xD;
      involvement in COVID-19 or serve as a non-specific marker of a severe systemic insult.&#xD;
      Cardiac myocyte and endothelial angiotensin converting enzyme-2 receptor may provide a portal&#xD;
      for viral infection in these cells.&#xD;
&#xD;
      There have been numerous reports of acute myocarditis in patients with COVID-19. Other&#xD;
      contributory mechanisms of cardiac Troponin elevation in patients with COVID-19 that are also&#xD;
      driven by a proinflammatory state include acute myocardial infarction due to atherosclerotic&#xD;
      plaque rupture (type 1) or demand ischemia (type 2), endothelial and microvascular&#xD;
      dysfunction, immune-mediated activation of coagulation and fibrinolytic systems, and possibly&#xD;
      stress cardiomyopathy.&#xD;
&#xD;
      We aim to identify disease-specific patterns of myocardial injury in COVID-19 using&#xD;
      non-invasive multi-modality cardiac imaging, paired with cytokine/chemokine testing,&#xD;
      immunophenotyping of peripheral blood cells and coagulation profiles.&#xD;
&#xD;
      A better understanding of the mechanisms underlying the excess mortality risk attributable to&#xD;
      myocardial injury in COVID-19 is needed and may help to improve patient care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID19</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients with COVID-19 and cardiac Troponin elevation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-invasive cardiac imaging</intervention_name>
    <description>Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with COVID-19 and elevated cardiac Troponin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years old&#xD;
&#xD;
          -  Confirmed COVID-19 infection&#xD;
&#xD;
          -  Troponin I elevation &gt;99th percentile of upper reference limit&#xD;
&#xD;
          -  Able to give written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child-bearing potential not using adequate contraception&#xD;
&#xD;
          -  Contra-indication to MRI scanning&#xD;
&#xD;
          -  Contrast allergy or contrast-nephropathy&#xD;
&#xD;
          -  Chronic kidney disease (eGFR &lt;30 mL/min/1.73 m2)&#xD;
&#xD;
          -  Previous myocardial infarction&#xD;
&#xD;
          -  Uncontrolled atrial fibrillation&#xD;
&#xD;
          -  Uncontrolled chronic inflammatory disease&#xD;
&#xD;
          -  Severe lymphopenia (&lt;0.2 x109/L)&#xD;
&#xD;
          -  Treatment with immunomodulatory therapies within the last month (excluding inhaled or&#xD;
             topical steroid therapy)&#xD;
&#xD;
          -  Any medical condition, in the opinion of the investigator, that prevents the&#xD;
             participant from lying flat during scanning, or from participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Tarkin, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <phone>+44(0)1223331504</phone>
    <email>jt545@cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tian Zhao, MA MBBS PhD</last_name>
    <phone>+44(0)1223331504</phone>
    <email>txz20@cam.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cambridge Univeristy Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <investigator>
      <last_name>Tian Zhao, MA MBBS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James HF Rudd, MD PhD FRCP FESC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziad Mallet, MD PhD FMedSci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deepa Gopalan, MD FRCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meritxell Nus, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Sage, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrej Ćorović, MA MB BChir</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Jason Tarkin</investigator_full_name>
    <investigator_title>Wellcome Clinical Research Career Development Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

